Mecasermin rinfabate

Drug Profile

Mecasermin rinfabate

Alternative Names: HGT-ROP-001; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Insmed
  • Developer Insmed; Shire
  • Class Antihyperglycaemics; Growth factors
  • Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Insulin resistance; Growth disorders; Retinopathy of prematurity; Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Retinopathy of prematurity
  • Market Withdrawal Growth disorders
  • Suspended Muscular dystrophies
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2016 Efficacy and adverse events data from a phase II trial in Retinopathy of prematurity released by Shire
  • 30 Jun 2016 Shire plans a phase III trial for Retinopathy of prematurity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top